Barry Brand, Chief Executive Officer and Director at CeNeRx will give a plenary keynote presentation on “Taking a Drug from Proof of Concept to the Market. The Role of Startups” at the 2nd CNS Diseases World Summit taking place on Sept 13-14, 2012 in San Francisco, CA.
Barry Brand brings 20 years of pharmaceutical industry experience and over a decade of leadership in neuroscience drug development to CeNeRx. As Vice President, Global Commercial Strategy–Neuroscience at GlaxoSmithKline (GSK), Mr. Brand was responsible for the commercial development of GSK’s clinical-stage Neuroscience pipeline. He oversaw global commercialization for marketed CNS products including Paxil/CR®, Wellbutrin/XL®, Zyban®, Lamictal®, Imitrex® and Requip®. As Paxil Marketing Director, Mr. Brand managed GSK’s largest assetachieving gross sales of $1.8 billionand was recognized as one of Advertising Age’s Top 100 Marketers. Mr. Brand has managed multiple co-promotion/co-development partnerships and has extensive lifecycle management and market development experience.
GTC's 2nd CNS Diseases World Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partneriing and deal-making.
Join your colleagues at this exciting CNS summit and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Stephen Brannan – VP at Takeda, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, Michael W. Weiner at UCSF, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Tony W. Ho - Vice President at AstraZeneca, and many more!
For more information, please visit www.gtcbio.com
Last updated on: 19/07/2012